Investigating new treatments for Alzheimer's disease using diabetes medications and natural compounds.
Comparison of Tirzepatide, Retatrutide, and Crocetin, for Mitigation of Alzheimer's-like Pathology in a Mouse Model of Alzheimer’s Disease
This study is looking at how new diabetes medications and a natural compound might help improve memory and brain health in mice that show signs of Alzheimer's, with the hope of finding better treatments for both diabetes and Alzheimer's disease.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nova Southeastern University NIH-funded |
| Lab location | 1 site (Fort Lauderdale-Davie, UNITED STATES) |
| Project ID | NIH-11043894 on NIH RePORTER |
What this research studies
This research explores the potential of new diabetes medications, tirzepatide and retatrutide, along with a natural compound called crocetin, to reduce Alzheimer's-like symptoms in a mouse model. The study aims to understand how these treatments can modify the underlying disease processes rather than just alleviate symptoms. By examining their effects on cognitive decline and neuroprotection, the research seeks to identify promising new therapies for Alzheimer's disease. The findings could lead to innovative treatment options that address both diabetes and Alzheimer's pathology.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are experiencing cognitive decline or have a diagnosis related to Alzheimer's disease.
Not a fit: Patients who are younger than 65 or do not have any cognitive impairment or Alzheimer's-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that not only treat Alzheimer's disease but also improve cognitive function in patients with diabetes.
How similar studies have performed: Previous research has shown that certain diabetes medications can have neuroprotective effects, indicating a promising avenue for further exploration in Alzheimer's treatment.
Where this research is happening
Fort Lauderdale-Davie, UNITED STATES
- Nova Southeastern University — Fort Lauderdale-Davie, United States (Active)
Researchers
- Principal investigator: Speth, Robert Charles — Nova Southeastern University
- Study coordinator: Speth, Robert Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.